Lakefront Biotherapeutics NV (LKFT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Lakefront Biotherapeutics NV’s revenue went from $160M in fiscal 2016 to $1.3B in fiscal 2025, growth of about 26.3% a year.
Net income in fiscal 2025 was $377M, a net margin of 28.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $1.0B and net income $877M.
Free cash flow was -$319M in fiscal 2025 and positive in 2 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.3B | $286M | $265M | $257M | $265M | $651M | $995M | $352M | $187M | $160M |
| Gross profit | — | $1.3B | $250M | — | $244M | $264M | — | — | — | — | — |
| Operating income | — | $347M | -$196M | -$98M | -$140M | -$194M | -$219M | $414M | -$54M | -$108M | -$12M |
| Net income | $877M | $377M | $77M | $234M | -$233M | -$117M | -$375M | $168M | -$34M | -$139M | $57M |
| EPS (diluted) | $13.25 | $5.72 | $1.17 | $3.55 | $-3.53 | $-1.77 | $-5.69 | $2.55 | $-0.51 | $-2.11 | $0.86 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +356.4% | +8.1% | +2.9% | −3.1% | −59.2% | −34.6% | +182.5% | +88.4% | +17.0% | +142.3% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$220M | -$303M | -$332M | -$449M | -$534M | -$571M | -$524M | $3.6B | -$163M | -$176M | $252M |
| Capital spending | -$2M | -$16M | -$17M | -$21M | -$29M | -$61M | -$52M | -$25M | -$12M | -$6M | -$5M |
| Free cash flow | -$222M | -$319M | -$350M | -$469M | -$563M | -$632M | -$577M | $3.6B | -$175M | -$183M | $248M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | $28M | $21M | $63M | $94M | $80M | $98M | $43M | $31M | $20M | $12M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $40M | $727M | $34M | $97M | $808M | — | $657M | $320M | $241M | — |
| Debt | — | $0 | — | — | — | — | — | $0 | — | — | $0 |
| Equity | — | $3.8B | $3.0B | $3.1B | $2.7B | $3.0B | $3.3B | $3.2B | $1.4B | $1.2B | $800M |
| Total assets | — | $4.0B | $4.3B | $4.8B | $5.0B | $5.9B | $7.0B | $6.8B | $1.6B | $1.5B | $1.1B |
| Shares (diluted) | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 97.3% | 87.4% | — | 95.0% | 99.3% | — | — | — | — | — |
| Operating margin | — | 26.5% | -68.3% | -36.8% | -54.3% | -73.2% | -33.7% | 41.6% | -15.3% | -57.6% | -7.6% |
| Net margin | 85.9% | 28.8% | 26.9% | 88.3% | -90.4% | -44.0% | -57.6% | 16.9% | -9.5% | -74.2% | 35.6% |
| FCF margin | -21.7% | -24.4% | -122.2% | -177.2% | -218.8% | -238.1% | -88.6% | 359.7% | -49.7% | -97.7% | 155.0% |
| ROIC | — | 7.2% | -5.1% | -2.5% | -4.1% | -5.1% | -5.3% | 10.1% | -3.1% | -7.0% | -1.5% |
| ROE | — | 9.9% | 2.6% | 7.6% | -8.6% | -3.9% | -11.4% | 5.2% | -2.4% | -11.4% | 7.1% |
Frequently asked questions
What is Lakefront Biotherapeutics NV’s annual revenue?
$1.3B in fiscal 2025 and $1.0B over the twelve months to September 30, 2026.
How much profit does Lakefront Biotherapeutics NV make?
Net income was $377M in fiscal 2025 (net margin 28.9%).
Is Lakefront Biotherapeutics NV’s revenue growing?
Yes: revenue rose 356.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.